β-Arrestins Regulate Stem Cell-Like Phenotype and Response to Chemotherapy in Bladder Cancer

Molecular Cancer Therapeutics
Georgios KallifatidisBal L Lokeshwar

Abstract

β-Arrestins are classic attenuators of G-protein-coupled receptor signaling. However, they have multiple roles in cellular physiology, including carcinogenesis. This work shows for the first time that β-arrestins have prognostic significance for predicting metastasis and response to chemotherapy in bladder cancer. β-Arrestin-1 (ARRB1) and β-arrestin-2 (ARRB2) mRNA levels were measured by quantitative RT-PCR in two clinical specimen cohorts (n = 63 and 43). The role of ARRBs in regulating a stem cell-like phenotype and response to chemotherapy treatments was investigated. The consequence of forced expression of ARRBs on tumor growth and response to Gemcitabine in vivo were investigated using bladder tumor xenografts in nude mice. ARRB1 levels were significantly elevated and ARRB2 levels downregulated in cancer tissues compared with normal tissues. In multivariate analysis only ARRB2 was an independent predictor of metastasis, disease-specific-mortality, and failure to Gemcitabine + Cisplatin (G+C) chemotherapy; ∼80% sensitivity and specificity to predict clinical outcome. ARRBs were found to regulate stem cell characteristics in bladder cancer cells. Depletion of ARRB2 resulted in increased cancer stem cell markers but ARRB2 ove...Continue Reading

References

Jan 1, 1989·Cancer Chemotherapy and Pharmacology·M M Tomayko, C P Reynolds
Jan 1, 1950·Cancer·W J YOUDEN
Jan 25, 2006·Proceedings of the National Academy of Sciences of the United States of America·F Gregory BuchananRaymond N DuBois
Jan 12, 2007·Journal of Cell Science·Lan Ma, Gang Pei
Feb 20, 2007·Annual Review of Physiology·Scott M DeWireSudha K Shenoy
Mar 9, 2007·Cancer Metastasis Reviews·Jing ZhangCarol E Cass
Apr 9, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Sandeep K RaghuwanshiRicardo M Richardson
Feb 21, 2009·BMC Cancer·Zi-Ke QinMu-Sheng Zeng
Aug 12, 2009·Proceedings of the National Academy of Sciences of the United States of America·Keith Syson ChanIrving L Weissman
Feb 7, 2012·Proceedings of the National Academy of Sciences of the United States of America·Jens-Peter VolkmerKeith S Chan
Oct 23, 2012·European Urology·Mahul B AminUNKNOWN International Consultation on Urologic Disease-European Association of Urology Consultation on Bladder Cancer 2012
Jul 3, 2013·Cancer Control : Journal of the Moffitt Cancer Center·Shilpa Gupta, Amit Mahipal
Nov 19, 2013·Current Stem Cell Research & Therapy·G Goodwin JineshAshish M Kamat
Dec 18, 2013·Science·Ophir ShalemFeng Zhang
Jul 31, 2014·Nature Methods·Neville E SanjanaFeng Zhang
Nov 22, 2014·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Mahul B AminMark S Soloway
Apr 16, 2015·Cancer·Matthew D GalskyUNKNOWN Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators
Jan 6, 2016·International Journal of Molecular Sciences·Tomokazu OhishiToshiro Migita
Feb 28, 2016·Molecular Cancer Research : MCR·Georgios KallifatidisBal L Lokeshwar
Jun 19, 2016·The Journal of Urology·Sam S ChangJames M McKiernan
Nov 23, 2016·Nature Reviews. Clinical Oncology·Samuel A Funt, Jonathan E Rosenberg
Jan 7, 2017·BJU International·Solomon L WolduYair Lotan
Aug 3, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Zhao YangTingyi Wen
Oct 27, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A RotteV Lemaire
May 4, 2018·Nature·Kelsie EichelMark von Zastrow

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Ribonucleases Deactivation

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on mechanisms that underlie deactivation of CRISPR ribonucleases. Here is the latest research.

CRISPR (general)

Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). CRISPR-Cas system enables the editing of genes to create or correct mutations. Discover the latest research on CRISPR here.

CRISPR Screens in Drug Resistance (ASM)

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

CRISPR in Cancer

CRISPR-Cas system enables the editing of genes to create or correct mutations. Given that genome instability and mutation is one of the hallmarks of cancer, the CRISPR-Cas system is being explored to genetically alter and eliminate cancer cells. Here is the latest research.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.